| Hybridoma technology: is it still useful? JZ Moraes, B Hamaguchi, C Braggion, ER Speciale, FBV Cesar, ... Current research in immunology 2, 32-40, 2021 | 50 | 2021 |
| da S.; Osaki, JH; Pereira, TM; Aguiar, RB Hybridoma Technology: Is It Still Useful? Curr JZ Moraes, B Hamaguchi, C Braggion, ER Speciale, FBV Cesar, ... Res. Immunol 2, 32-40, 2021 | 5 | 2021 |
| Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response TA Silva, RB Aguiar, M Mori, GE Machado, B Hamaguchi, MFM Machado, ... Gene Therapy 30 (7), 598-602, 2023 | 3 | 2023 |
| Alternative Methods to Animal Use for Monoclonal Antibody Generation and Production JZ de Moraes, B Hamaguchi, C Braggion, E Speciale, F Cesar, G Soares, ... Monoclonal Antibodies, 2020 | 3 | 2020 |
| Anti-idiotypic monoclonal antibody 10. D7, mimicking vascular endothelium growth factor (VEGF), inhibits metastasis formation TDA Da Silva, GE Machado, B Hamaguchi, RB Aguiar, JZ DE MORAES IMMUNO MEXICO 2018, 991, 0 | | |
